Yahoo is fairly accurate, huge short interest might reverse some of the bleeding near term, but this thing has traded like a biotech startup instead of the simple SAAS it truly is. Their are more competitors in this space, both large and small, than Carter's has pills. Their stats are totally out of whack with the industry and you don't need an MBA from Harvard to see this thing for what it is. Been short at 43 and more at 40, will take some off the table tomorrow given the overreaction to the earnings miss and see how the rest plays out. It won't go to zero, but it could visit 20 and get into line with its peers.
Although Athenaclinicals is reputed to be as good as competitive EMR's, I'm not sure the end users are convinced. This is really a chance for the MDRX, QSII, eClincal, etc. to stick the knife in. I think Athena's best out is to put itself up for sale. Question is, what price would ATHN fetch. Seems to me that CERN would be interested at some price.